drugset
drugset / Trial / NCT00638963

Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)

NCT00638963 ↗

Phase 2 Terminated 6 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to determine whether temozolomide can be used as a prophylaxis against brain recurrence in participants with metastatic breast cancer.

Timeline

Start
2008-10-02
Primary completion
2010-06-30
Completion
2010-06-30

Outcome

Outcome not reported

Stopped (Enrollment): “Terminated due to poor accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 75 mg/m2 Oral

Indications

brain neoplasm breast neoplasm secondary neoplasm